Prime Signed Value-Based Deal With EMD Serono for Mavenclad
Prime Therapeutics LLC recently unveiled that it had signed a value-based agreement for a relatively new multiple sclerosis (MS) drug with a complicated treatment regimen and high price tag.
In early June, the PBM said it had signed a deal with EMD Serono, Inc. for Mavenclad (cladribine) by which Prime would be financially compensated based on the rate at which members discontinue the therapy or switch to another MS drug over the typical course of treatment.
Study Finds Fertility Program Prevents Medication Waste, Loss, Missed DosesREAD MORE
AbbVie Files Lawsuit Against Alternate Funding Company Payer Matrix Alleging ‘Fraudulent and Deceptive Scheme’READ MORE